GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Equity-to-Asset

Bionik Laboratories (Bionik Laboratories) Equity-to-Asset : -0.49 (As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bionik Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $-1.64 Mil. Bionik Laboratories's Total Assets for the quarter that ended in Mar. 2023 was $3.36 Mil. Therefore, Bionik Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was -0.49.

The historical rank and industry rank for Bionik Laboratories's Equity-to-Asset or its related term are showing as below:

BNKL's Equity-to-Asset is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.47
* Ranked among companies with meaningful Equity-to-Asset only.

Bionik Laboratories Equity-to-Asset Historical Data

The historical data trend for Bionik Laboratories's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Equity-to-Asset Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.72 0.37 0.63 -0.49

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.40 0.14 -0.14 -0.49

Competitive Comparison of Bionik Laboratories's Equity-to-Asset

For the Medical Care Facilities subindustry, Bionik Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories's Equity-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Equity-to-Asset falls into.



Bionik Laboratories Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bionik Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=-1.641/3.362
=-0.49

Bionik Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )=Total Stockholders Equity/Total Assets
=-1.641/3.362
=-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionik Laboratories  (OTCPK:BNKL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Bionik Laboratories Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291